Targeting growth factors in arthritis: A rational for restoring the IGF-I response in chondrocytes

Current Rheumatology Reviews

Volumn 4, Issue 4, 2008, Pages 266-276

  Van de Loo, Fons A ^a   Veenbergen, Sharon ^a   Van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GLUCOSE TRANSPORTER 4; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 17; METHOTREXATE; PROTEIN P53; PROTEOGLYCAN; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING; UBIQUITIN;

ARTHROPATHY; ARTICLE; BIOLOGICAL ACTIVITY; BONE; BONE EROSION; BONE REMODELING; CARTILAGE; CARTILAGE DEGENERATION; CHONDROCYTE; DISEASE COURSE; EPIGENETICS; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 78649390785     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339708786263861     Document Type: Article

References (102)

1. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005; 16: 421-39.
2. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 1991; 11: 393-412.
3. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum 2005; 35(1): 24-34.
4. Denley A, Bonython ER, Booker GW, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 2004; 18: 2502-12.
5. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001; 61: 7318-24.
6. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20: 267-75.
7. Porter RM, Akers RM, Howard RD, Forsten-Williams K. Transcriptional and proteolytic regulation of the insulin-like growth factor-I system of equine articular chondrocytes by recombinant equine interleukin-1beta. J Cell Physiol 2006; 209: 542-50.
8. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol 2005; 142: 44-52.
9. Kooijman RK, Scholtens LE, Rijkers GT, Zegers BJ. Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol 1995; 25: 931-5.
10. Baudler S, Baumgartl J, Hampel B, et al. Insulin-like growth factor-1 controls type 2 T cell-independent B cell response. J Immunol 2005; 174: 5516-25.
11. Wynes MW, Riches DW. Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol 2003; 171: 3550-9.
12. Wang J, Zhou J, Bondy CA. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J 1999; 13: 1985-90.
13. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF)receptor gene reveals an essential role of IGF signalling in bone matrix mineralization. J Biol Chem 2002; 277: 44005-12.
14. Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000; 141: 2674-82.
15. Jiang J, Lichtler AC, Gronowicz GA, et al. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone 2006; 39: 494-504.
16. Mukherjee A, Rotwein P. Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor? Growth Horm IGF Res 2007; 17: 179-85.
17. Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1990; 116: 408-19.
18. Curtis AJ, Ng CK, Handley CJ, Robinson HC. Effect of insulinlike growth factor-I on the synthesis and distribution of link protein and hyaluronan in explant cultures of articular cartilage. Biochim Biophys Acta 1992; 1135: 309-17.
19. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi AH. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys 1988; 267: 416-25
20. Shakibaei M, Seifarth C, John T, Rahmanzadeh M, Mobasheri A. Igf-I extends the chondrogenic potential of human articular chondrocytes in vitro: molecular association between Sox9 and Erk1/2. Biochem Pharmacol 2006; 72: 1382-95.
21. Zhou G, Zheng Q, Engin F, et al. Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci USA 2006; 103: 19004-9.
22. Joosten LA, Schalkwijk J, van den Berg WB, van de Putte LB. Chondrocyte unresponsiveness to insulin-like growth factor-1. A novel pathogenetic mechanisms for cartilage destruction in experimental arthritis. Agents Actions 1989; 26: 193-95.
23. Loeser RF, Shanker G, Carlson CS, et al. Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: studies in a non-human primate model of naturally occurring disease. Arthritis Rheum 2000; 43: 2110-20.
24. Tavera C, Abribat T, Reboul P, et al. IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. Osteoarthritis Cartilage 1996; 4: 263-74.
25. Ekenstedt KJ, Sonntag WE, Loeser RF, Lindgren BR, Carlson CS. Effects of chronic growth hormone and insulin-like growth factor 1 deficiency on osteoarthritis severity in rat knee joints. Arthritis Rheum 2006; 54: 3850-8.
26. Zhai G, Rivadeneira F, Houwing-Duistermaat JJ, et al. Insulinlike growth factor I gene promoter polymorphism, collagen type II alpha1 (COL2A1) gene, and the revalence of radiographic osteoarthritis: the Rotterdam Study. Ann Rheum Dis 2004; 63: 544-8.
27. Olney RC, Wilson DM, Mohtai M, Fielder PJ, Smith RL. Interleukin-1 and tumor necrosis factor-alpha increase insulinlike growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995; 146: 279-86.
28. Sunic D, McNeil JD, Rayner TE, Andress DL, Belford DA. Regulation of insulin-like growth factor-binding protein-5 by insulin-like growth factor I and interleukin-1alpha in ovine articular chondrocytes. Endocrinology 1998; 139: 2356-62.
29. Karna E, Miltyk W, Surazyński A, Pałka JA. Protective effect of hyaluronic acid on interleukin-1-induced deregulation of beta (1)-integrin and insulin-like growth factor-I receptor signalling and collagen biosynthesis in cultured human chondrocytes. Mol Cell Biochem 2008; 308: 57-64.
30. Verschure PJ, Van Marle J, Joosten LA, van den Berg WB. Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis. Ann Rheum Dis 1995; 54: 645-53.
31. Verschure PJ, Marle JV, Joosten LA, Helsen MM, Lafeber FP, Berg WB. Localization of insulin-like growth factor-1 receptor in human normal and osteoarthritic cartilage in relation to proteoglycan synthesis and content. Br J Rheumatol 1996; 35: 1044-55.
32. Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factoralpha, and interleukin-6. Lymphokine Cytokine Res 1993; 12: 219-23.
33. Schalkwijk J, Joosten LA, van den Berg WB, van Wyk JJ, van de Putte LB. Insulin-like growth factor stimulation of chondrocyte proteoglycan synthesis by human synovial fluid. Arthritis Rheum 1989; 32: 66-71.
34. Schalkwijk J, Joosten LA, van den Berg WB, van de Putte LB. Chondrocyte nonresponsiveness to insulin-like growth factor 1 in experimental arthritis. Arthritis Rheum 1989; 32: 894-900.
35. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998; 41: 1141-51.
36. Evans CH, Watkins SC, Stefanovic-Racic M. Nitric oxide and cartilage metabolism. Methods Enzymol 1996; 269: 75-88.
37. Amin AR, Di Cesare PE, Vyas P, et al. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 1995; 182: 2097-102.
38. Hauselmann HJ, Stefanovic-Racic M, Michel BA, Evans CH. Differences in nitric oxide production by superficial and deep human articular chondrocytes: implications for proteoglycan turnover in inflammatory joint diseases. J Immunol 1998; 160: 1444-8.
39. Hauselmann HJ, Oppliger L, Michel BA, Stefanovic-Racic M, Evans CH. Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture. FEBS Lett 1994; 352: 361-4.
40. Cao M, Westerhausen-Larson A, Niyibizi C, et al. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 1997; 324: 305-10.
41. Studer RK, Levicoff E, Georgescu H, Miller L, Jaffurs D, Evans CH. Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRbeta tyrosine phosphorylation. Am J Physiol Cell Physiol 2000; 279: C961-9.
42. Studer RK. Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo. Osteoarthritis Cartilage 2004; 12: 863-9.
43. Studer RK, Decker K, Melhem S, Georgescu H. Nitric oxide inhibition of IGF-1 stimulated proteoglycan synthesis: role of cGMP. J Orthop Res 2003; 21: 914-21
44. Van de Loo FA, Arntz OJ, van Enckevort FH, van Lent PL, van den Berg WB. Reduced cartilage proteoglycan loss during zymosaninduced gonarthritis in NOS2-deficient mice and in anti-interleukin-1-treated wild-type mice with unabated joint inflammation. Arthritis Rheum 1998; 41: 634-46.
45. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002; 46: 2349-57.
46. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-73.
47. Kasperkovitz PV, Verbeet NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 233-9.
48. Van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48: 2132-45.
49. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995; 182: 1825-31.
50. De Hooge AS, van de Loo FA, Koenders MI, et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosaninduced arthritis: exacerbation of joint inflammation in STAT-1 geneknockout mice. Arthritis Rheum 2004; 50: 2014-23.
51. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002; 169: 6610-6.
52. Murray PJ. The JAK-STAT signalling pathway: input and output integration. J Immunol 2007; 178: 2623-9.
53. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signalling and immune responses by SOCS proteins. Arthritis Res Ther 2005; 7: 100-10.
54. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-65.
55. Kamura T, Maenaka K, Kotoshiba S, et al. VHL-box and SOCSbox domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 2004; 18: 3055-65.
56. Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signalling 1 function. J Immunol 2004; 172: 7510-8.
57. Isomäki P, Alanärä T, Isohanni P, et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1538-46.
58. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. Suppressor of cytokine signalling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 2003; 111: 915-24.
59. Wong PK, Egan PJ, Croker BA, et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006; 116: 1571-81.
60. Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 979-90.
61. Lehmann U, Schmitz J, Weissenbach M, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signalling through gp130. J Biol Chem 2003; 278: 661-71.
62. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108: 1781-88.
63. Smeets RL, Veenbergen S, Arntz OJ, et al. A novel role for suppressor of cytokine signalling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum 2006; 54: 1518-28.
64. Liu E, Côté JF, Vuori K. Negative regulation of FAK signalling by SOCS proteins. EMBO J 2003; 22: 5036-46.
65. Frobøse H, Rønn SG, Heding PE, et al. Suppressor of cytokine signalling-3 inhibits interleukin-1 signalling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 2006; 20: 1587-96.
66. Emanuelli B, Glondu M, Filloux C, Peraldi P, Van OE. The potential role of SOCS-3 in the interleukin-1beta-induced desensitization of insulin signalling in pancreatic beta-cells. Diabetes 2004; 53: S97-S103.
67. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signalling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-9.
68. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van OE. SOCS-3 is an insulin-induced negative regulator of insulin signalling. J Biol Chem 2000; 275: 15985-91.
69. Keller SR, Lamphere L, Lavan BE, Kuhne MR, Lienhard GE. Insulin and IGF-I signalling through the insulin receptor substrate 1. Mol Reprod Dev 1993; 35: 346-51.
70. Oh CD, Chun JS. Signalling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1. J Biol Chem 2003; 278: 36563-71.
71. Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signalling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 2000; 278: 38-43.
72. Ehlting C, Häussinger D, Bode JG. Sp3 is involved in the regulation of SOCS3 gene expression. Biochem J 2005; 387: 737-45.
73. Chadjichristos C, Ghayor C, Kypriotou M, et al. Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J Biol Chem 2003; 278: 39762-72.
74. Zaman K, Palmer LA, Doctor A, Hunt JF, Gaston B. Concentrationdependent effects of endogenous S-nitrosoglutathione on gene regulation by specificity proteins Sp3 and Sp1. Biochem J 2004, 380: 67-74.
75. Studer RK. Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo. Osteoarthritis Cartilage 2004; 12: 863-9.
76. Peralta S, Carrascosa JM, Gallardo N, Ros M, Arribas C. Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction. Biochem Biophys Res Commun 2002; 296: 425-8.
77. Price JS, Waters JG, Darrah C, et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell 2002; 1: 57-65.
78. Roach HI, Yamada N, Cheung KS, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum 2005; 52: 3110-24.
79. Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 1996; 8: 495-500.
80. Bell MC, Carroll GJ. Leukaemia inhibitory factor (LIF) suppresses proteoglycan synthesis in porcine and caprine cartilage explants. Cytokine 1995; 7: 137-41.
81. Van de Loo FA, Arntz OJ, Van den Berg WB. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 1997; 9: 453-62.
82. Cai L, Yin JP, Starovasnik MA, et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001; 16: 10-21.
83. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signalling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signalling. J Cell Sci 2006; 119: 380-7.
84. Laubner K, Kieffer TJ, Lam NT, Niu X, Jakob F, Seufert J. Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signalling 3 in pancreatic α-cells. Diabetes 2005; 54: 3410-7.
85. Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003; 48: 3118-29.
86. Otero M, Lago R, Gómez R, Lago F, Gomez-Reino JJ, Gualillo O. Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/ interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci 2007; 81: 1452-60.
87. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 2007; 66: 1616-21.
88. Cucchiarini M, Thurn T, Weimer A, Kohn D, Terwilliger EF, Madry H. Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. Arthritis Rheum 2007; 56: 158-67.
89. Qiao B, Padilla SR, Benya PD. Transforming growth factor (TGF)-α-activated kinase 1 mimics and mediates TGF-α-induced stimulation of type II collagen synthesis in chondrocytes independent of Col2a1 transcription and Smad3 signalling. J Biol Chem 2005; 280: 17562-71.
90. Jallali N, Ridha H, Thrasivoulou C, Butler P, Cowen T. Modulation of intracellular reactive oxygen species level in chondrocytes by IGF-1, FGF, and TGF-α1. Connect Tissue Res 2007; 48: 149-58.
91. Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints. Lab Invest 1998; 78: 133-42.
92. Bakker AC, van de Loo FA, van Beuningen HM, et al. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthritis Cartilage 2001; 9: 128-36.
93. Van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-beta injections. Osteoarthritis Cartilage 2000; 8: 25-33.
94. Mi Z, Ghivizzani SC, Lechman ER, et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43: 2563-70.
95. Rogachefsky RA, Dean DD, Howell DS, Altman RD. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate. Osteoarthritis Cartilage 1993; 1: 105-14.
96. Nixon AJ, Fortier LA, Williams J, Mohammed H. Enhanced repair of extensive articular defects by insulin-like growth factor-I-laden fibrin composites. J Orthop Res 1999; 17: 475-87.
97. Izal I, Acosta CA, Ripalda P, Zaratiegui M, Ruiz J, Forriol F. IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage. Arch Orthop Trauma Surg 2008; 128: 239-47.
98. Morisset S, Frisbie DD, Robbins PD, Nixon AJ, McIlwraith CW. IL-1ra/IGF-1 gene therapy modulates repair of microfractured chondral defects. Clin Orthop Relat Res 2007; 462: 221-8.
99. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor α treatment. Ann Rheum Dis 2005; 64: 1137-40.
100. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-72.
101. Verschure PJ, Joosten LA, Van de Loo FA, Van den Berg WB. IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints. Ann Rheum Dis 1995; 54: 976-82.
102. Granado M, Martín AI, Villanúa MA, López-Calderón A. Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol Endocrinol Metab 2007; 292: E1656-65.